AI
LLY icon

Accredited Investors’s Eli Lilly LLY Stock Holding History

Accredited Investors’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.78M Sell
3,151
-1,099
-26% -$1.12M 0.16% 53
2026
Q1 		$3.91M Buy
4,250
+264
+7% +$268K 0.21% 51
2025
Q4 		$4.28M Buy
3,986
+176
+5% +$168K 0.23% 48
2025
Q3 		$2.91M Sell
3,810
-41
-1% -$30.5K 0.16% 56
2025
Q2 		$3M Buy
3,851
+561
+17% +$436K 0.18% 52
2025
Q1 		$2.72M Buy
3,290
+44
+1% +$36.6K 0.17% 52
2024
Q4 		$2.51M Buy
3,246
+43
+1% +$35.6K 0.15% 55
2024
Q3 		$2.84M Sell
3,203
-15
-0.5% -$13.5K 0.16% 52
2024
Q2 		$2.91M Sell
3,218
-36
-1% -$28.8K 0.18% 47
2024
Q1 		$2.53M Buy
3,254
+168
+5% +$120K 0.16% 54
2023
Q4 		$1.8M Sell
3,086
-20
-0.6% -$11.7K 0.13% 62
2023
Q3 		$1.67M Buy
+3,106
New +$1.6M 0.13% 60
2023
Q2 		– Sell
-2,999
Closed -$1.03M – 195
2023
Q1 		$1.03M Buy
2,999
+5
+0.2% +$1.69K 0.08% 76
2022
Q4 		$1.1M Sell
2,994
-27
-0.9% -$9.57K 0.09% 71
2022
Q3 		$977K Buy
3,021
+84
+3% +$26.6K 0.11% 69
2022
Q2 		$952K Sell
2,937
-8
-0.3% -$2.4K 0.11% 74
2022
Q1 		$843K Buy
2,945
+8
+0.3% +$2.06K 0.08% 86
2021
Q4 		$811K Sell
2,937
-141
-5% -$35.7K 0.07% 88
2021
Q3 		$711K Buy
3,078
+105
+4% +$25.9K 0.08% 83
2021
Q2 		$682K Buy
2,973
+8
+0.3% +$1.61K 0.07% 86
2021
Q1 		$554K Sell
2,965
-215
-7% -$42.1K 0.07% 93
2020
Q4 		$537K Buy
3,180
+146
+5% +$21.8K 0.09% 88
2020
Q3 		$449K Sell
3,034
-5
-0.2% -$774 0.09% 91
2020
Q2 		$499K Buy
3,039
+7
+0.2% +$1.07K 0.1% 86
2020
Q1 		$421K Buy
3,032
+8
+0.3% +$1.1K 0.1% 88
2019
Q4 		$397K Sell
3,024
-166
-5% -$19.2K 0.07% 98
2019
Q3 		$357K Buy
3,190
+73
+2% +$8.13K 0.07% 98
2019
Q2 		$345K Buy
3,117
+204
+7% +$24K 0.07% 100
2019
Q1 		$378K Buy
2,913
+69
+2% +$8.39K 0.08% 90
2018
Q4 		$329K Sell
2,844
-118
-4% -$13.2K 0.07% 86
2018
Q3 		$318K Buy
2,962
+10
+0.3% +$1K 0.08% 91
2018
Q2 		$252K Buy
2,952
+117
+4% +$9.61K 0.07% 95
2018
Q1 		$219K Buy
2,835
+20
+0.7% +$1.61K 0.06% 97
2017
Q4 		$238K Sell
2,815
-127
-4% -$10.8K 0.07% 101
2017
Q3 		$252K Sell
2,942
-317
-10% -$26K 0.07% 98
2017
Q2 		$268K Buy
3,259
+14
+0.4% +$1.14K 0.07% 80
2017
Q1 		$273K Sell
3,245
-2
-0.1% -$160 0.07% 84
2016
Q4 		$239K Sell
3,247
-10
-0.3% -$745 0.06% 85
2016
Q3 		$261K Buy
3,257
+32
+1% +$2.56K 0.07% 80
2016
Q2 		$254K Hold
3,225
– – 0.07% 79
2016
Q1 		$232K Sell
3,225
-1,139
-26% -$86.2K 0.06% 81
2015
Q4 		$368K Buy
4,364
+83
+2% +$6.89K 0.09% 65
2015
Q3 		$359K Buy
4,281
+10
+0.2% +$844 0.1% 60
2015
Q2 		$357K Sell
4,271
-21
-0.5% -$1.6K 0.09% 50
2015
Q1 		$312K Buy
4,292
+13
+0.3% +$926 0.08% 57
2014
Q4 		$296K Sell
4,279
-96
-2% -$6.48K 0.09% 57
2014
Q3 		$284K Buy
4,375
+13
+0.3% +$823 0.09% 57
2014
Q2 		$272K Buy
+4,362
New +$260K 0.09% 55

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
ONB
Old National Bancorp Evansville, Indiana $5.02B AUM 25.65% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
GIM
Goelzer Investment Management Carmel, Indiana $2.29B AUM 39.12% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Accredited Investors's LLY Position: Q2 2026 in Review

Accredited Investors reduced its Eli Lilly (LLY) stake by 26% in Q2 2026, selling an estimated $1.12M and leaving 3,151 shares worth $3.78M. The position accounts for 0.16% of the portfolio, ranked #53.

Accredited Investors first reported a position in LLY in Q2 2014 and has held it in 48 quarters since. The position peaked at $4.28M in Q4 2025. 1,711 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Accredited Investors held 3,151 shares of Eli Lilly worth $3.78M as of Q2 2026.
  • Accredited Investors sold 1,099 Eli Lilly shares in Q2 2026, an estimated $1.12M.
  • Eli Lilly made up 0.16% of Accredited Investors's portfolio in Q2 2026, its #53 holding.
  • Accredited Investors first reported a position in Eli Lilly in Q2 2014 and has held it in 48 quarters since.
  • Accredited Investors's Eli Lilly position peaked at $4.28M in Q4 2025.
  • 1,711 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Accredited Investors's 13F filing for Q2 2026, filed 21 Jul 2026.